文献速递心血管MRUS

恩格列净改善非糖尿病心力衰竭的舒张功能障碍及左心室纤维化/僵硬:多模态研究

Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study.
PubMed 文献 · JACC Cardiovasc Imaging · 2020-10-29

恩格列净组在2个月时经超声心动图、应变成像、心脏磁共振和有创血流动力学评估均显示舒张功能显著改善,并减少心肌间质纤维化、改善一氧化氮信号和肌联蛋白磷酸化;结论提示恩格列净改善非糖尿病心衰猪模型的舒张功能并减轻左心室和心肌细胞僵硬。

要点

  • 在非糖尿病心衰猪模型中,恩格列净治疗2个月可显著改善多项舒张功能指标。
  • 恩格列净可减少心肌间质纤维化,并改善一氧化氮信号和肌联蛋白磷酸化。
  • 心肌葡萄糖消耗与舒张功能负相关,酮体消耗与舒张功能正相关。

核心结论

  • 恩格列净改善非糖尿病心衰猪模型的舒张功能,减轻组织学和分子水平重构,并降低左心室和心肌细胞僵硬。

研究设计与样本

  • 研究类型:非糖尿病猪心力衰竭模型,随机对照实验。
  • 样本量:原文未报告动物数量。
  • 设备/序列:心脏磁共振(CMR)、三维超声心动图、有创血流动力学、原代培养心肌细胞体外松弛实验。
  • 参考标准:组织学和分子评估心肌纤维化及信号通路,同步冠状动静脉采血分析心肌代谢物消耗。

关键影像表现/征象

  • 恩格列净组在2个月时常规超声心动图显示e'和彩色M型传播速度更高,E/e'比值、Tei指数、等容舒张时间和左房大小更低。
  • 应变成像显示应变成像舒张指数、等容舒张期和舒张早期应变率及解旋均改善。
  • CMR显示峰值充盈率更高、首次充盈量更大。
  • 有创血流动力学证实恩格列净组峰值左室压力下降速率(-dP/dt)更好、Tau更短、舒张末期压力-容积关系(EDPVR)更低、充盈压力降低。
  • 恩格列净在影像、组织学和分子水平减少心肌间质纤维化,并改善一氧化氮信号和肌联蛋白磷酸化。

诊断标准与关键数值

  • 原文未报告诊断标准、敏感度、特异度、AUC、阈值或分级标准。

临床应用与阅片要点

  • 原文未给出临床阅片或报告建议。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The purpose of this study was to investigate the effect of empagliflozin on diastolic function in a nondiabetic heart failure with reduced ejection fraction (HFrEF) scenario and on the pathways causing diastolic dysfunction.

BACKGROUND: This group demonstrated that empagliflozin ameliorates adverse cardiac remodeling, enhances myocardial energetics, and improves left ventricular systolic function in a nondiabetic porcine model of HF. Whether empagliflozin also improves diastolic function remains unknown. Hypothetically, empagliflozin would improve diastolic function in HF mediated both by a reduction in interstitial myocardial fibrosis and an improvement in cardiomyocyte stiffness (titin phosphorylation).

METHODS: HF was induced in nondiabetic pigs by 2-h balloon occlusion of proximal left anterior descending artery. Animals were randomized to empagliflozin or placebo for 2 months. Cardiac function was evaluated with cardiac magnetic resonance (CMR), 3-dimensional echocardiography, and invasive hemodynamics. In vitro relaxation of cardiomyocytes was studied in primary culture. Myocardial samples were obtained for histological and molecular evaluation. Myocardial metabolite consumption was analyzed by simultaneous blood sampling from coronary artery and coronary sinus.

RESULTS: Despite similar initial ischemic myocardial injury, the empagliflozin group showed significantly improved diastolic function at 2 months, assessed by conventional echocardiography (higher e' and color M-mode propagation velocity, lower E/e' ratio, myocardial performance Tei index, isovolumic relaxation time, and left atrial size), echocardiography-derived strain imaging (strain imaging diastolic index, strain rate at isovolumic relaxation time and during early diastole, and untwisting), and CMR (higher peak filling rate, larger first filling volume). Invasive hemodynamics confirmed improved diastolic function with empagliflozin (better peak LV pressure rate of decay (-dP/dt), shorter Tau, lower end-diastolic pressure-volume relationship (EDPVR), and reduced filling pressures). Empagliflozin reduced interstitial myocardial fibrosis at the imaging, histological and molecular level. Empagliflozin improved nitric oxide signaling (endothelial nitric oxide synthetase [eNOS] activity, nitric oxide [NO] availability, cyclic guanosine monophosphate (cGMP) content, protein kinase G [PKG] signaling) and enhanced titin phosphorylation (which is responsible for cardiomyocyte stiffness). Indeed, isolated cardiomyocytes exhibited better relaxation in empagliflozin-treated animals. Myocardial consumption of glucose and ketone bodies negatively and positively correlated with diastolic function, respectively.

CONCLUSIONS: Empagliflozin ameliorates diastolic function in a nondiabetic HF porcine model, mitigates histological and molecular remodeling, and reduces both left ventricle and cardiomyocyte stiffness.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study. JACC Cardiovasc Imaging. 2020. PMID: 33129742. doi:10.1016/j.jcmg.2020.07.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。